Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
Microsoft PowerPoint - Roche IR Event EULAR Final.ppt
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Roche</strong>’s autoimmune portfolio<br />
Expanding breadth of indications<br />
Phase I<br />
Phase II<br />
Phase III<br />
All Autoimmune RA<br />
Oral DMARDs<br />
Biologics<br />
Phase I<br />
R1295 (RA)<br />
R3421 (AI)<br />
R3477 (AI)<br />
BR3-FC (RA) GNE<br />
PNP Inh (AI) Biocryst<br />
S1P1 (MS) Actelion<br />
Phase II<br />
R1503 (RA)<br />
MabThera<br />
(RRMS) GNE<br />
R1295<br />
MabThera<br />
(RA DMARD)<br />
Actemra (RA)<br />
Actemra (sJIA)<br />
CellCept (LN)<br />
Phase III<br />
Pamapimod<br />
(p38 inh)<br />
Ocrelizumab<br />
(RA)<br />
MabThera<br />
(PPMS) GNE<br />
MabThera<br />
(ANCA av) GNE<br />
MabThera<br />
(SLE) GNE<br />
MabThera<br />
(LN) GNE<br />
Ocrelizumab<br />
Actemra<br />
Filed/Approved<br />
MabThera<br />
(RA TNF)<br />
MabThera<br />
55